Skip to main content
Premium Trial:

Request an Annual Quote

Meridian Bioscience Fiscal Q3 Revenues Rise 7 Percent as Acquisition Looms

NEW YORK – Meridian Bioscience reported on Friday morning a 7 percent year-over-year increase in its fiscal third quarter revenues, one month after announcing it will be acquired by a newly formed affiliate of SD Biosensor and SJL Partners.

The Cincinnati-based life science and diagnostics firm recorded total revenues of $67.8 million compared to $63.5 million a year ago. The revenues were in line with Meridian's preliminary results released in July.

Its life science revenues for the quarter were down 21 percent at $25.4 million compared to $32.3 million a year ago. Within the segment, Meridian Bioscience's fiscal Q3 molecular reagent product revenues fell 62 percent year over year to $7.7 million from $20.4 million, while immunological reagent revenues rose 48 percent year over year to $17.6 million from $11.9 million.

The shift from molecular to immunological regents was driven by lower overall demand in fiscal 2022 for molecular tests related to COVID-19, Meridian said in a statement.

Meanwhile, Meridian Bioscience's diagnostics revenues were up 36 percent year over year to $42.4 million from $31.2 million.

Within diagnostics, revenues for molecular assays grew 11 percent to $4.9 million from $4.4 million, while revenues from non-molecular assays grew 40 percent to $37.5 million from $26.8 million. For non-molecular assays, the increase was driven by demand for BreathTek tests and a rise in LeadCare product sales after a product recall affected fiscal Q3 2021 sales. Within the company's disease categories, gastrointestinal assays contributed most to the diagnostics revenues, rising to $22.7 million from $17.8 million in 2021.

Meridian Bioscience's fiscal Q3 net loss was $7.3 million, or $.16 per share, compared to $11.7 million, or $.26 per share a year ago. On an adjusted basis, EPS was $.16.

The firm noted that it paid $11.8 million in litigation and select legal costs during the quarter, compared to $438,000 in 2021. The increase was due to the accrual of $10 million to possibly settle its legal matter with the US Department of Justice related to its subsidiary Magellan's LeadCare product line, as well as $1.8 million in attorneys' fees related to the dispute, the company disclosed in its form 10-Q filed with the US Securities and Exchange Commission.

The firm finished the quarter with $83.5 million in cash and cash equivalents.

In morning trading on the Nasdaq, Meridian's shares were up 2 percent at $32.24.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.